XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Fair Value of Derivative Liability (Details) - Development Derivative Liability - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Fair value at beginning of period $ 4,597 $ 0
Non-cash research and development expense 3,547 5,795
Cash receipts from SFJ 750 1,500
Change in the fair value of development derivative liability 2,713 4,312
Fair value at end of period $ 11,607 $ 11,607